quinidine/главоболие

Линкът е запазен в клипборда

Изберете тип сортиране

Страница 1 от 22 резултата

An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

BACKGROUND Pseudobulbar affect (PBA) is associated with neurological disorders or injury affecting the brain, and characterized by frequent, uncontrollable episodes of crying and/or laughing that are exaggerated or unrelated to the patient's emotional state. Clinical trials establishing

[Plasma level studies of quinidine retard, their significance for dosage and onset of effect].

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

A new sustained-action preparation of quinidine-bisulfate (BM-Chinidin Retard) was investigated in 21 patients. After a single oral dose of 1 g peak plasma levels are reached within 3-4 hours with an unsubstantial decrease during the following 4 hours. After 2 g in three divided doses within 12

Dextromethorphan/Quinidine in Migraine Prophylaxis: An Open-label Observational Clinical Study.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

OBJECTIVE This study aimed to assess potential efficacy and safety of dextromethorphan/quinidine (DMQ) in prophylactic treatment of migraine in patients with multiple sclerosis (MS) with superimposed pseudobulbar affect (PBA). METHODS Multiple sclerosis patients with superimposed PBA and comorbid

Dextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

BACKGROUND Dextromethorphan (DM) / quinidine (Q) was approved for pseudobulbar affect (PBA) treatment based on efficacy and safety trials in patients with PBA caused by amyotrophic lateral sclerosis or multiple sclerosis. The PRISM II trial evaluated DM/Q as PBA treatment in patients with stroke,

PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

BACKGROUND Phase 3 trials supporting dextromethorphan/quinidine (DM/Q) use as a treatment for pseudobulbar affect (PBA) were conducted in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). The PRISM II study provides additional DM/Q experience with PBA secondary to

Fatal quinidine-induced thrombocytopenia following open-heart surgery.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

Three patients developed quinidine-induced thrombocytopenia within 3 months of our initiating quinidine therapy after open-heart surgery. One patient recovered from thrombocytopenic purpura after quinidine was discontinued. The 2 other patients presented with thrombocytopenic purpura and gingival

Propafenone versus quinidine slow-release for the treatment of chronic ventricular arrhythmias.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

The efficacy and side-effects of oral propafenone 300 mg b.i.d. were compared to those of quinidine slow-release 800 mg b.i.d. in a randomized double-blind placebo controlled cross-over study in 12 patients with symptomatic premature ventricular complexes (PVCs). Furthermore during steady-state the

Dextromethorphan and quinidine in adult patients with uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

BACKGROUND Pain associated with diabetic peripheral neuropathy (DPN) has a substantial negative impact on patients' quality of life. OBJECTIVE The primary objective of this study was to evaluate the tolerability of capsules containing dextromethorphan (DM) and quinidine (Q) in patients with painful

Flecainide versus quinidine for treatment of chronic ventricular arrhythmias. A multicenter clinical trial.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

The antiarrhythmic efficacy and safety of oral flecainide acetate and quinidine sulfate were compared in a double-blind, 16-center parallel trial involving 280 patients with chronic premature ventricular complexes (PVCs). Eighty-five percent of the flecainide patients had at least 80% suppression of

Intravenous dextromethorphan/quinidine inhibits activity of dura-sensitive spinal trigeminal neurons in rats.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

BACKGROUND Migraine is a chronic neurological disorder characterized by episodes of throbbing headaches. Practically all medications currently used in migraine prophylaxis have a number of substantial disadvantages and use limitations. Therefore, the further search for principally new prophylactic

An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

Dextromethorphan (DM)/quinidine (Q) is an approved treatment for pseudobulbar affect (PBA) based on trials in amyotrophic lateral sclerosis or multiple sclerosis. PRISM II evaluated DM/Q effectiveness and tolerability for PBA secondary to dementia, stroke, or traumatic brain injury; dementia cohort

Falciparum malaria--present day problems. An experience with 425 cases.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

Clinical details and present day problems encountered in 425 cases of falciparum malaria (PF) are reported. 10.11% had taken chloroquine prior to reporting to us. Parasitic count done in 23.05% cases lacked correlation with severity of disease. Pattern of fever varied markedly but 5.4% were afebrile

Involvement of gap junction channels in the pathophysiology of migraine with aura.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

Migraine is a common, recurrent, and disabling primary headache disorder with a genetic component which affects up to 20% of the population. One third of all patients with migraine experiences aura, a focal neurological disturbance that manifests itself as visual, sensitive or motor symptoms

Moricizine: a new class I antiarrhythmic.

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

The chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage of the Class I antiarrhythmic agent moricizine hydrochloride are reviewed. Moricizine is chemically similar to the phenothiazines but does not appear to block dopaminergic receptors. Its major

[Antiarrhythmic effect of disopyramide in ventricular extrasystole and auricular fibrillation].

Само регистрирани потребители могат да превеждат статии

Вход / Регистрация

Disopyramide (B 712) was tested in 39 patients with chronic arrhythmias of different kind: 23 cases with atrial fibrillation, 16 cases with ventricular ectopic beats, two cases with supraventricular tachycardias. The effect of disopyramide was compared to a pretreatment with one or several

Предишна
1
2
Следваща

Присъединете се към нашата
страница във facebook

Herbal & Natural Medicine

Най-пълната база данни за лечебни билки, подкрепена от науката

Работи на 55 езика
Билкови лекове, подкрепени от науката
Разпознаване на билки по изображение
Интерактивна GPS карта - маркирайте билките на място (очаквайте скоро)
Прочетете научни публикации, свързани с вашето търсене
Търсете лечебни билки по техните ефекти
Организирайте вашите интереси и бъдете в крак с научните статии, клиничните изследвания и патентите

Въведете симптом или болест и прочетете за билките, които биха могли да помогнат, напишете билка и вижте болестите и симптомите, срещу които се използва.
* Цялата информация се базира на публикувани научни изследвания